Pharma & Life Sciences
Built for clinical operations, regulatory affairs, and pharmacovigilance teams that need cryptographically reproducible outputs. Every Sovereign agent produces a 21 CFR Part 11–grade receipt with multi-party attestation and on-demand replay.
Every agent run produces an HMAC + Ed25519 signed receipt with a Merkle-chained audit trail. Selective disclosure lets you reveal one field (e.g. final verdict) to an inspector without exposing the rest of the patient record.
An expert-critic rubric specifically tuned for ICH-GCP protocol deviations ships in the core library. The critic flags blockers (eligibility violations, dosing errors, IB version mismatches) before any output reaches a CRA's desk.
Sign each output with sponsor + CRO + investigator HMACs. M-of-N quorum policies. Cross-witness forgery is cryptographically impossible. Strongest possible audit signal for monitoring visits.
Verifier layer 6 scores every claim sentence-by-sentence against supplied source documents. Hallucinated citations are dropped; ungrounded sentences are flagged before delivery.
Every Annex IV control is mapped to a Sovereign capability with audit-ready evidence text. Quarterly attestation letters auto-generate as signed PDFs your CMC + regulatory team can sign and submit.
"Draft a Type C meeting briefing book section on our new bioequivalence design."
Briefing-book section + signed receipt + replay-ready audit trail. What took 14 days takes 36 hours.
"Review yesterday's pharmacovigilance signals and draft DSURs sections."
Draft DSUR section + cited evidence map + signed attestation. Reviewer time -70%.
"Run a regulatory-intelligence sweep for FDA letters citing our class of compounds."
Weekly digest with full provenance. Replayable any time a regulator asks 'how did you know?'
Every other AI platform stops at “explainable.” Sovereign Matrix answers with on-demand cryptographic reproducibility. A regulator pastes a receipt id — Sovereign re-runs the same input through the same agent and reports whether the output drifted. That’s the audit signal pharma’s been waiting for.
Schedule a procurement deep-dive